We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Treatment of Severe Aplastic Anemia with Combined Immunosuppression (Antithymocyte Globulin and High-Dose Methylprednisolone).
- Authors
Hinterberger-Fischer, M.; Hinterberger, W.; Höckern, P.; Schmidmeier, W.; Gadner, H.; Geissler, K.; Kos, M.; Schwarzinger, I.; Neumann, E.; Niessner, H.; Schindler, J.; Lechner, K.
- Abstract
Fifteen patients with transfusion-dependent severe aplastic anemia (SAA) were treated with combined immunosuppression consisting of horse-antithymocyte globulin (ATG; Atgam®, Upjohn) and high-dose 6-methylprednisolone (MP). Oxymetholone was scheduled for 2 years but was discontinued in 7 patients after 10-385 days due to liver toxicity. Serious side effects usually seen in ATG monotherapy were rare during combined immunosuppression. Currently 12 of 15 patients are alive 110-1,275 days (median 475.5) after start of treatment. One patient has received too short treatment to be evaluated. All the others are transfusion-independent. Three patients died; two from septicemia before hemopoietic recovery could be expected and one after relapse. Our results confirm that (1) the addition of high-dose MP abrogates the side effects of ATG mono-therapy, and (2) the addition of MP does not counteract, but rather enhances the beneficial effect of ATG in SAA. We recommend combined immunosuppressive treatment with ATG and high-dose MP as a highly feasible, safe and effectful therapy for patients with transfusion-dependent SAA. Copyright © 1986 S. Karger AG, Basel
- Publication
Acta Haematologica, 1986, Vol 76, Issue 4, p196
- ISSN
0001-5792
- Publication type
Article
- DOI
10.1159/000206055